综述与专论：神经退行性疾病中的TDP-43蛋白聚集和相变

随着全球老龄化人口的急剧增加,神经退行性变已经成为危害公共健康的主要疾病。在神经退行性疾病(肌萎缩侧索硬化症(ALS)、额颞叶变性病(FTLD)和阿尔茨海默病(AD)等)患者脑组织中均能观察到蛋白质聚集形成的包涵体,其中TAR DNA结合蛋白43 (TDP-43)是主要成分之一。目前已发现多个TDP-43基因突变与家族性ALS密切相关。TDP-43属RNA/DNA结合蛋白,参与细胞内多种RNA代谢过程,它可以在细胞核和细胞质之间穿梭,通过相变诱导胞质和核质包涵体的形成。本文简要总结了TDP-43在体内和体外聚集以及发生相变的研究进展。理解TDP-43的异常相变将有助于寻找神经退行性疾病的潜在治疗靶点。     

TDP-43在神经退行性疾病中的功能和作用

核蛋白TAR DNA/RNA结合蛋43(TDP-43)目前被认为是肌萎缩侧索硬化症(amyotrophic lateral sclerosis,ALS)、额颞叶变性(frontotemporal lobar degeneration,FTLD)等神经退行性疾病的病理学标记蛋白。在中枢神经系统中,TDP-43作为必要的转录调控因子,参与mRNA前体的剪接,维持RNA稳态和运输。在突变和过表达TDP-43的转基因啮齿类动物模型中,受损伤的神经元呈现出胞核和胞质中TDP-43泛素化、磷酸化聚集,以及细胞周期进程的改变。在此,着重阐述基于TDP-43突变或过表达建立神经退行性疾病动物模型的研究进展,探讨其发病机制、病理学改变及治疗方法。     

TDP-43在缺血性脑卒中的作用

TDP-43(Transactive response DNA binding protein 43, TDP-43)最初被认为是神经退行性疾病的病理学标记蛋白,研究发现其参与脑缺血损伤的发生发展。在现有研究的基础上,简要介绍TDP-43的结构与功能以及TDP-43在脑缺血后的表达变化及其在脑缺血后调节炎症反应、线粒体功能障碍、自噬等方面的作用。     

科研快讯

正PLOS Biology:ALS蛋白质动力学强调自缔合和聚合之间微妙的平衡发表于《PLOS Biology》期刊的一项新研究,ALS-相关蛋白质TDP-43部分由于其正常功能而迈出通向病理性聚合的最初步骤。这项研究由Liangzhong Lim、Jianxing Song和新加坡国立大学的同事们进行,支持新兴观点:神经系统疾病中的蛋白质聚合,可能是聚合蛋白质正常功能的夸大。正常TDP-43蛋白的细胞质聚合物存在于几乎所有形式的肌萎缩侧索硬化(ALS)和许多额颞叶痴呆(FTD)病例中。研究人员在约97%的ALS患者和约45%的FTD患者中观察到TDP-43聚合。它也涉及一系列其他神经退行性疾病,包括阿尔茨海默病。     

基于GNM方法研究人TDP-43-DNA相互作用动力学及关键位点

TAR DNA结合蛋白43（transactive response DNA binding protein 43，TDP-43），一种可变剪切因子，可以特异性地结合富含TG序列的DNA，涉及多种神经退行性疾病. 分子动力学模拟方法虽然是研究分子间相互作用强有力的工具，但它非常耗时，且难以对有大的构象变化的体系进行充分采样来研究其变构行为. 本工作使用粗粒化的基于弹性势的高斯网络模型（Gaussian network model，GNM）研究人TDP-43与靶标DNA间相互作用的动力学. 进一步地，利用本课题组之前提出的基于GNM的热力学循环方法识别TDP-43与DNA相互作用的关键残基，其微扰引起了大的结合自由能的变化. DNA结合后，TDP-43上富含正电残基的loop1和loop3片段有较大的柔性损失，这反映了它们在识别和结合中的诱导契合作用. 另外发现，基于热力学循环的方法不仅识别到一些与DNA特异性相互作用有关的重要残基，而且识别到一些远离结合界面但在结合引起的分子构象变化中发挥重要作用的残基. 本研究有助于理解TDP-43与DNA的特异性相互作用，可为药物设计提供重要信息，另外该方法可以很方便地拓展到其他蛋白质-核酸相互作用动力学的研究.     

Hsp70在神经退行性疾病中的作用机制研究进展

热休克蛋白Hsp70 (heat shock protein 70, Hsp70)是一类广泛存在的分子伴侣。阿尔茨海默病(Alzheimer’s disease)、帕金森病(Parkinson’s disease)等神经退行性疾病共同的病理特征是错误折叠的蛋白质(包括Tau、α-突触核蛋白、TDP-43、朊蛋白和多聚谷氨酰胺蛋白)形成有毒性的寡聚体或淀粉样纤维。大量的研究表明,Hsp70可以调控这些蛋白质的代谢进程,包括将错误折叠的蛋白质重折叠、抑制蛋白质聚集以及降解错误折叠的蛋白质。Hsp70在发挥功能时需要相对应的辅助分子伴侣的帮助。该文详细论述了Hsp70抑制Tau蛋白病、α-突触核蛋白病、TDP-43蛋白病、传染性海绵状脑病以及多聚谷氨酰胺疾病的作用机制,重点阐述了Hsp70对神经退行性疾病中错误折叠蛋白质聚集和毒性的抑制作用,并讨论和展望了Hsp70在神经退行性疾病的治疗中存在的挑战和机遇。     

RNA结合蛋白与神经退行性疾病

神经退行性疾病是一类导致神经元细胞退化、功能丧失的疾病。随着RNA结合蛋白TDP-43和FUS被发现与神经退行性疾病渐冻人症(amyotrophic lateral sclerosis,ALS)密切相关,人们越来越多地关注RNA结合蛋白与神经退行性疾病的关系。大多数RNA结合蛋白都存在一个类似于prion的结构域,这个结构域使其容易发生积聚,并与神经毒性的产生相关。RNA结合蛋白参与应激颗粒的形成,应激颗粒的形成可能与神经退行性疾病相关,这进一步揭示了RNA结合蛋白在这类疾病中可能发挥作用。     

液-液相分离与神经系统退行性疾病

细胞区室化(compartmentation)有助于分隔不同的生化反应，使其相互不产生干扰。有膜细胞器是通过生物膜把细胞内不同的空间分隔，进而实现细胞区室化。研究发现，细胞区室化也会通过细胞中无膜细胞器实现，但核仁等无膜区室的形成机制一直未得到明确。“液-液相分离”(liquid-liquid phase separation, LLPS)机制的发现，为解开无膜区室的谜题提供了全新的思路。现在认为，多种蛋白质和RNA也是通过LLPS机制形成局部的高浓度冷凝物，发挥更强或独特的基因表达调控、细胞信号转导等功能。LLPS的形成主要依赖于蛋白质和/或核酸之间的多价态非共价键相互作用，主要包括由低复杂序列区域介导的相分离及由多个重复结构域间特异性作用介导的相分离。组分浓度、pH和翻译后修饰等条件均能改变分子多价相互作用的强度，从而调节相分离和相变过程。蛋白质相分离的失调与肌萎缩性侧索硬化症、阿尔茨海默病、亨廷顿舞蹈症和帕金森病等多种神经退行性疾病的发生有关。在这些退行性疾病中，已发现TDP-43、FUS、Ataxin-2、Tau蛋白等致病基因的突变，以及修饰会导致LLPS异常而形成病理特征性的...     

环氧合酶在神经变性疾病神经元进行性损伤中起重要作用

环氧合酶(COX)是非甾体抗炎药的主要作用靶点.自从上世纪90年代初被发现至今,COX已被证实广泛参与炎性反应过程.小胶质细胞是介导"神经炎性反应"的主要细胞类型,过去十年中,COX通路参与小胶质细胞激活及神经变性过程的机制取得了很大进展.本文对该领域的新近研究成果予以论述,并以三大神经变性疾病,即阿尔采末病(AD)、帕金森病(PD)和肌萎缩侧索硬化症(ALS)为例,对COX在其发病中的作用加以阐释,突出该领域的研究热点,为神经变性疾病发病机制及药物治疗研究提供新的思路.     

RNA-binding proteins in neurological diseases

Emerging studies support that RNA-binding proteins(RBPs)play critical roles in human biology and pathogenesis.RBPs are essential players in RNA processing and metabolism,including pre-mRNA splicing,polyadenylation,transport,surveillance,mRNA localization,mRNA stability control,translational control and editing of various types of RNAs.Aberrant expression of and mutations in RBP genes affect various steps of RNA processing,altering target gene function.RBPs have been associated with various diseases,including neurological diseases.Here,we mainly focus on selected RNA-binding proteins including Nova-1/Nova-2,HuR/HuB/HuC/HuD,TDP-43,Fus,Rbfox1/Rbfox2,QKI and FMRP,discussing their function and roles in human diseases.     

Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis

The TAR DNA-binding protein 43 (TDP-43) has been identified as the major disease protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin inclusions (FTLD-U), defining a novel class of neurodegenerative conditions: the TDP-43 proteinopathies. The first pathogenic mutations in the gene encoding TDP-43 (TARDBP) were recently reported in familial and sporadic ALS patients, supporting a direct role for TDP-43 in neurodegeneration. In this study, we report the identification and functional analyses of two novel and one known mutation in TARDBP that we identified as a result of extensive mutation analyses in a cohort of 296 patients with variable neurodegenerative diseases associated with TDP-43 histopathology. Three different heterozygous missense mutations in exon 6 of TARDBP (p.M337V, p.N345K, and p.I383V) were identified in the analysis of 92 familial ALS patients (3.3%), while no mutations were detected in 24 patients with sporadic ALS or 180 patients with other TDP-43-positive neurodegenerative diseases. The presence of p.M337V, p.N345K, and p.I383V was excluded in 825 controls and 652 additional sporadic ALS patients. All three mutations affect highly conserved amino acid residues in the C-terminal part of TDP-43 known to be involved in protein-protein interactions. Biochemical analysis of TDP-43 in ALS patient cell lines revealed a substantial increase in caspase cleaved fragments, including the approximately 25 kDa fragment, compared to control cell lines. Our findings support TARDBP mutations as a cause of ALS. Based on the specific C-terminal location of the mutations and the accumulation of a smaller C-terminal fragment, we speculate that TARDBP mutations may cause a toxic gain of function through novel protein interactions or intracellular accumulation of TDP-43 fragments leading to apoptosis.     

TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration

Accumulations of aggregated proteins are a key feature of the pathology of all of the major neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS) was brought into this fold quite recently with the discovery of TDP-43 (TAR DNA binding protein, 43 kDa) inclusions in nearly all ALS cases. In part this discovery was fueled by the recognition of the clinical overlap between ALS and frontotemporal lobar degeneration, where ubiquitinated TDP-43 inclusions were first identified. Later the identification of TDP-43 mutations in rare familial forms of ALS confirmed that altered TDP-43 function can be a primary cause of the disease. However, the simple concept that TDP-43 is an aggregation-prone protein that forms toxic inclusions capable of promoting neurodegeneration has not been upheld by initial investigations. This review discusses observations from human pathology, cell culture and animal model systems, to highlight our somewhat murky understanding of the relationship between TDP-43 aggregation and neurodegeneration.     

Interaction with Polyglutamine Aggregates Reveals a Q/N-rich Domain in TDP-43

The identification of pathologic TDP-43 aggregates in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration, followed by the discovery of dominantly inherited point mutations in TDP-43 in familial ALS, have been critical insights into the mechanism of these untreatable neurodegenerative diseases. However, the biochemical basis of TDP-43 aggregation and the mechanism of how mutations in TDP-43 lead to disease remain enigmatic. In efforts to understand how TDP-43 alters its cellular localization in response to proteotoxic stress, we found that TDP-43 is sequestered into polyglutamine aggregates. Furthermore, we found that binding to polyglutamine aggregates requires a previously uncharacterized glutamine/asparagine (Q/N)-rich region in the C-terminal domain of TDP-43. Sequestration into polyglutamine aggregates causes TDP-43 to be cleared from the nucleus and become detergent-insoluble. Finally, we observed that sequestration into polyglutamine aggregates led to loss of TDP-43-mediated splicing in the nucleus and that polyglutamine toxicity could be partially rescued by increasing expression of TDP-43. These data indicate pathologic sequestration into polyglutamine aggregates, and loss of nuclear TDP-43 function may play an unexpected role in polyglutamine disease pathogenesis. Furthermore, as Q/N domains have a strong tendency to self-aggregate and in some cases can function as prions, the identification of a Q/N domain in TDP-43 has important implications for the mechanism of pathologic aggregation of TDP-43 in ALS and other neurodegenerative diseases.     

TDP-43: a novel neurodegenerative proteinopathy

Over the past decade, it has become clear that there is a significant overlap in the clinical spectrum of frontotemporal lobar degeneration and amyotrophic lateral sclerosis (ALS). The identification of TDP-43 as the major disease protein in the pathology of both frontotemporal lobar degeneration with ubiquitin inclusions and ALS provides the first molecular link for these diseases. Pathological TDP-43 is abnormally phosphorylated, ubiquitinated, and cleaved to generate carboxy-terminal fragments in affected brain regions. The normal nuclear expression of TDP-43 is also reduced leading to the hypothesis that sequestration of TDP-43 in pathological inclusions contributes to disease pathogenesis. Thus, TDP-43 is the newest member of the growing list of neurodegenerative proteinopathies, but unique in that it lacks features of brain amyloidosis.     

TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis

In this review, we summarize recent advances in understanding frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders that are collectively known as TDP-43 proteinopathies, since transactive response DNA-binding protein 43 (TDP-43) was recently shown to be the major component of the ubiquitinated inclusions that are their pathological hallmarks. TDP-43 proteinopathies are distinct from most other neurodegenerative disorders because TDP-43 inclusions are not amyloid deposits. Besides TDP-43-positive inclusions, both sporadic and familial forms of FTLD and ALS have the pathologic TDP-43 signature of abnormal hyperphosphorylation, ubiquitination and C-terminal fragments in affected brain and spinal cord, suggesting that they share a common mechanism of pathogenesis. Thus, these findings support the concept that FTLD and ALS represent a clinicopathologic spectrum of one disease, that is, TDP-43 proteinopathy.     

TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage

Abnormal aggregates of transactive response DNA-binding protein-43 (TDP-43) and its hyperphosphorylated and N-terminal truncated C-terminal fragments (CTFs) are deposited as major components of ubiquitinated inclusions in most cases of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U). The mechanism underlying the contribution of TDP-43 to the pathogenesis of these neurodegenerative diseases remains unknown. In this study, we found that a 2-5-fold increase in TDP-43 expression over the endogenous level induced death of NSC34 motor neuronal cells and primary cortical neurons. TDP-43-induced death is associated with up-regulation of Bim expression and down-regulation of Bcl-xL expression. siRNA-mediated reduction of Bim expression attenuates TDP-43-induced death. Accumulated evidence indicates that caspases are activated in neurons of ALS and FTLD-U patients, and activated caspase-mediated cleavage of TDP-43 generates CTFs of TDP-43. Here, we further found that the ER (endoplasmic reticulum) stress- or staurosporine-mediated activation of caspases leads to cleavage of TDP-43 at Asp(89) and Asp(169), generating CTF35 (TDP-43-(90-414)) and CTF27 (TDP-43-(170-414)) in cultured neuronal cells. In contrast to TDP-43, CTF27 is unable to induce death while it forms aggregates. CTF35 was weaker than full-length TDP-43 in inducing death. A cleavage-resistant mutant of TDP-43 (TDP-43-D89E/D169E) showed stronger death-inducing activity than wild-type TDP-43. These results suggest that disease-related activation of caspases may attenuate TDP-43-induced toxicity by promoting TDP-43 cleavage.     

Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) are major neurodegenerative diseases with TDP-43 pathology. Here we investigated the effects of methylene blue (MB) and dimebon, two compounds that have been reported to be beneficial in phase II clinical trials of Alzheimer’s disease (AD), on the formation of TDP-43 aggregates in SH-SY5Y cells. Following treatment with 0.05 μM MB or 5 μM dimebon, the number of TDP-43 aggregates was reduced by 50% and 45%, respectively. The combined use of MB and dimebon resulted in a 80% reduction in the number. These findings were confirmed by immunoblot analysis. The results indicate that MB and dimebon may be useful for the treatment of ALS, FTLD-U and other TDP-43 proteinopathies.